Accelerate biotechnology

Blog: Biotech startups – understanding the ecosystem for success

Biotechnology is in the midst of a great era of innovation, with an ever-expanding toolbox of drug modalities spawning development of exciting new vaccines, medicines and therapies. Today’s ecosystem for innovation in drug development looks quite different compared to ten or twenty years ago, with many more symbiotic relationships between venture capital (VC)-backed pharma and…


Scientific publication: AdV-20-42-42, promising adenoviral vector for gene therapy and vaccine product development

Adenoviruses are being explored as vectors for vaccines against various infectious diseases, such as COVID-19, and as vectors for gene therapy purposes against many heritable diseases. Pre-existing immune responses towards adenoviral vectors can limit the use of a vector. Therefore, a significant interest exists to vectorize novel adenoviral types that have low seroprevalence in the…


Scientific publication: Stable, high yield expression of HIV gp145

We are proud to announce that the peer-reviewed journal Biologicals has now published our work on the high yield expression of an HIV envelope protein. Despite numerous advances in the understanding of HIV and AIDS, the search for a potent anti-HIV vaccine continues. The envelope glycoproteins found on the surface of the HIV virus are…


Article: How the Netherlands became a key player for vaccine development

The Netherlands has a long history in the life sciences industry. Especially in the field of vaccine development and manufacturing, this small country has always played a significant role. Lately, the rich history proved a fertile ground for developing and manufacturing a wide variety of SARS-CoV-2 vaccines. The website Invest in Holland has written an…


Scientific publication: Formulation development live rotavirus vaccine candidate for use low- and middle-income countries

We are proud to announce a third publication coming from our rotavirus vaccine project, funded by the Bill & Melinda Gates Foundation. The peer-reviewed journal Human Vaccines & Immunotherapeutics has published scientific data generated together with the University of Kansas on the formulation development of a live-attenuated, human neonatal rotavirus vaccine candidate (RV3-BB). The three…


Article: Interview Menzo Havenga on Future of Vector Vaccines

Now that the mRNA-based SARS-CoV-2 vaccines turn out to be successful, is there still a future for vector-based vaccines? “Absolutely”, says expert Menzo Havenga (CEO, Batavia Biosciences). In an interview with a Dutch local newspaper, Menzo explains some of the benefits of the use of viral vectors, such as the stability and costs. Additionally, viral…


Scientific publication: STEP® vectors for rapid generation of stable CHO cell lines for difficult-to-express proteins

Many proteins produced in CHO cells need evaluation for their clinical and commercial potential. Traditional methods based on stable clone generation are slow and unsuitable for screening larger numbers of proteins, while transient expression technologies are fast but unpredictable regarding product quality and lacking an optional path to subcloning. Therefore, we developed an alternative and…


Blog: How to work with a CDMO for viral vectors: 5 steps to success

Viral vector technologies are at the heart of many promising new therapies, such as vaccines, gene therapies, immune-oncology therapies and other advanced therapy medicinal products (ATMPs). In this rapidly evolving and competitive landscape, there is little scope for error or inefficiency in the development process. A contract manufacturing and development organization (CDMO) that specializes in…

COVID-19 Message

Please read the message from our executive management regarding the precautionary measures at Batavia Biosciences.